## Hyman M Schipper

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1109958/publications.pdf Version: 2024-02-01

		47006	31849
115	10,618	47	101
papers	citations	h-index	g-index
100	100	100	00550
122	122	122	20553
all docs	docs citations	times ranked	citing authors

HYMAN M SCHIDDED

#	Article	IF	CITATIONS
1	Dysregulation of a Heme Oxygenase–Synuclein Axis in Parkinson Disease. NeuroSci, 2022, 3, 284-299.	1.2	2
2	Characterization and heme oxygenaseâ€1 content of extracellular vesicles in human biofluids. Journal of Neurochemistry, 2021, 157, 2195-2209.	3.9	9
3	Heme oxygenase-1 in blood and saliva during acute psychosis: A pilot study. Psychiatry Research, 2021, 299, 113857.	3.3	1
4	Salivary Heme Oxygenase-1: A Potential Biomarker for Central Neurodegeneration. Journal of Central Nervous System Disease, 2021, 13, 117957352110291.	1.9	10
5	Strategic Timing of Clial <i>HMOX1</i> Expression Results in Either Schizophrenia-Like or Parkinsonian Behavior in Mice. Antioxidants and Redox Signaling, 2020, 32, 1259-1272.	5.4	8
6	Salivary microRâ€153 and microRâ€223 Levels as Potential Diagnostic Biomarkers of Idiopathic Parkinson's Disease. Movement Disorders, 2020, 35, 468-477.	3.9	78
7	The sinister face of heme oxygenase-1 in brain aging and disease. Progress in Neurobiology, 2019, 172, 40-70.	5.7	147
8	Dentate Gyrus Immaturity in Schizophrenia. Neuroscientist, 2019, 25, 528-547.	3.5	15
9	Glial <i>HMOX1</i> expression promotes central and peripheral αâ€synuclein dysregulation and pathogenicity in parkinsonian mice. Glia, 2019, 67, 1730-1744.	4.9	25
10	Greater palatine block for V2 trigeminal neuralgia: Case report. Special Care in Dentistry, 2019, 39, 208-213.	0.8	4
11	Evaluation of salivary heme oxygenaseâ€1 as a potential biomarker of early Parkinson's disease. Movement Disorders, 2018, 33, 583-591.	3.9	40
12	Did the Kabbalah Anticipate Heisenbergâ $\in$ $^{ m Ms}$ Uncertainty Principle?. , 2018, , .		0
13	Kabbalah and the Physics of David Bohm. , 2018, , .		Ο
14	Biomarkers in Epidemiologic Research: Definition, Classification, and Implication. , 2017, , 135-139.		2
15	Cysteine-rich whey protein isolate (Immunocal®) ameliorates deficits in the GFAP.HMOX1 mouse model of schizophrenia. Free Radical Biology and Medicine, 2017, 110, 162-175.	2.9	11
16	Astrocyte heme oxygenase-1 reduces mortality and improves outcome after collagenase-induced intracerebral hemorrhage. Neurobiology of Disease, 2017, 102, 140-146.	4.4	54
17	Parkinsonian features in aging GFAP.HMOX1 transgenic mice overexpressing human HO-1 in the astroglial compartment. Neurobiology of Aging, 2017, 58, 163-179.	3.1	29
18	Assessing neuronal density in periâ€infarct cortex with PET: Effects of cortical topology and partial volume correction. Human Brain Mapping, 2017, 38, 326-338.	3.6	10

#	Article	IF	CITATIONS
19	P2â€155: Development and Validation of a Salivary TAU Biomarker in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P674.	0.8	0
20	The Impact of Gonadal Hormones on the Expression of Human Neurological Disorders. Neuroendocrinology, 2016, 103, 417-431.	2.5	13
21	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
22	Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis. Clinical Neuropharmacology, 2015, 38, 127-131.	0.7	9
23	Astrocyte Overexpression of Heme Oxygenase-1 Improves Outcome After Intracerebral Hemorrhage. Stroke, 2015, 46, 1093-1098.	2.0	49
24	A Heme Oxygenase-1 Transducer Model of Degenerative and Developmental Brain Disorders. International Journal of Molecular Sciences, 2015, 16, 5400-5419.	4.1	53
25	Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study. Biomarkers in Medicine, 2015, 9, 89-97.	1.4	4
26	Salivary biomarkers of oxidative stress: A critical review. Free Radical Biology and Medicine, 2015, 85, 95-104.	2.9	85
27	Heme oxygenaseâ€1 modulates microRNA expression in cultured astroglia: Implications for chronic brain disorders. Glia, 2015, 63, 1270-1284.	4.9	38
28	ls glial heme oxygenase-1 suppression in neurodegenerative disorders permissive for neural repair?. Neural Regeneration Research, 2015, 10, 208.	3.0	5
29	Increased microRNA-34c abundance in Alzheimer's disease circulating blood plasma. Frontiers in Molecular Neuroscience, 2014, 7, 2.	2.9	122
30	Neurotherapeutic effects of novel <scp>HO</scp> â€1 inhibitors <i>in vitro</i> and in a transgenic mouse model of Alzheimer's disease. Journal of Neurochemistry, 2014, 131, 778-790.	3.9	45
31	Sex Hormone, Pituitary, Parathyroid, and Adrenal Disorders and the Nervous System. , 2014, , 369-397.		1
32	Astroglial heme oxygenase-1 and the origin of corpora amylacea in aging and degenerating neural tissues. Experimental Neurology, 2014, 254, 78-89.	4.1	36
33	P2-064: HO-1/STEROL-OXYSTEROL INTERACTIONS IN ALZHEIMER'S DISEASE: A SYNTHESIS. , 2014, 10, P493-P49	3.	Ο
34	Schizophrenia-Like Features in Transgenic Mice Overexpressing Human HO-1 in the Astrocytic Compartment. Journal of Neuroscience, 2012, 32, 10841-10853.	3.6	63
35	Unregulated brain iron deposition in transgenic mice overâ€expressing <i><scp>HMOX</scp>1</i> in the astrocytic compartment. Journal of Neurochemistry, 2012, 123, 325-336.	3.9	47
36	Neurodegeneration with brain iron accumulation — Clinical syndromes and neuroimaging. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 350-360.	3.8	119

#	Article	IF	CITATIONS
37	Altered redox homeostasis in human diabetes saliva. Journal of Oral Pathology and Medicine, 2012, 41, 235-241.	2.7	22
38	Apolipoprotein E: Implications for AD neurobiology, epidemiology and risk assessment. Neurobiology of Aging, 2011, 32, 778-790.	3.1	69
39	Presymptomatic apolipoprotein E genotyping for Alzheimer's disease risk assessment and prevention. , 2011, 7, e118-e123.		22
40	ARAC - The Montreal Jewish General Hospital Alzheimer Risk Assessment Clinic. Canadian Journal of Neurological Sciences, 2011, 38, 600-611.	0.5	3
41	Risk Profiles of Alzheimer Disease. Canadian Journal of Neurological Sciences, 2011, 38, 580-592.	0.5	20
42	Heme oxygenase-1 in Alzheimer disease: a tribute to Moussa Youdim. Journal of Neural Transmission, 2011, 118, 381-387.	2.8	53
43	Stress Gene Deregulation in Alzheimer Peripheral Blood Mononuclear Cells. , 2011, , 251-263.		2
44	Biological Markers and Alzheimer Disease: A Canadian Perspective. International Journal of Alzheimer's Disease, 2010, 2010, 1-7.	2.0	7
45	Altered Salivary Redox Homeostasis in Patients with Systemic Sclerosis. Journal of Rheumatology, 2010, 37, 1858-1863.	2.0	12
46	A GSTM3 polymorphism associated with an etiopathogenetic mechanism in Alzheimer disease. Neurobiology of Aging, 2010, 31, 34-45.	3.1	33
47	A Novel Experimental Heme Oxygenase-1–Targeted Therapy for Hormone-Refractory Prostate Cancer. Cancer Research, 2009, 69, 8017-8024.	0.9	110
48	Brain Iron Deposition in Aging and Disease: Role of HO-1. , 2009, , 125-139.		0
49	Suppression of Glial HO-1 Activitiy as a Potential Neurotherapeutic Intervention in AD. Current Alzheimer Research, 2009, 6, 424-430.	1.4	55
50	Salivary DNA, lipid, and protein oxidation in nonsmokers with periodontal disease. Free Radical Biology and Medicine, 2009, 46, 914-921.	2.9	110
51	Isocratic rapid liquid chromatographic method for simultaneous determination of carotenoids, retinol, and tocopherols in human serum. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 1077-1083.	2.3	47
52	Impact of heme oxygenase†on cholesterol synthesis, cholesterol efflux and oxysterol formation in cultured astroglia. Journal of Neurochemistry, 2009, 108, 72-81.	3.9	27
53	HOâ€1â€mediated macroautophagy: a mechanism for unregulated iron deposition in aging and degenerating neural tissues. Journal of Neurochemistry, 2009, 109, 776-791.	3.9	87
54	Heme oxygenaseâ€1 and neurodegeneration: expanding frontiers of engagement. Journal of Neurochemistry, 2009, 110, 469-485.	3.9	243

#	Article	IF	CITATIONS
55	The Parkinson diseaseâ€associated A30P mutation stabilizes αâ€synuclein against proteasomal degradation triggered by heme oxygenaseâ€1 overâ€expression in human neuroblastoma cells. Journal of Neurochemistry, 2009, 110, 719-733.	3.9	61
56	Brain sterol dysregulation in sporadic AD and MCI: relationship to heme oxygenaseâ€1. Journal of Neurochemistry, 2009, 110, 1241-1253.	3.9	57
57	Methodology for Discovery of Alzheimer's Disease Blood-Based Biomarkers. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2009, 64A, 636-645.	3.6	35
58	Dramatic Shifts in Circulating CD4 but not CD8 T Cell Subsets in Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 17, 91-103.	2.6	173
59	Near-Infrared Spectroscopy of Blood Plasma for Diagnosis of Sporadic Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 17, 391-397.	2.6	39
60	MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders. Current Genomics, 2009, 10, 154-168.	1.6	194
61	Inherited Disorders of Brain Iron Homeostasis. , 2009, , 251-276.		3
62	Diurnal variations in salivary protein carbonyl levels in normal and cognitively impaired human subjects. Age, 2008, 30, 1-9.	3.0	36
63	Diagnosis and treatment of dementia: 2. Diagnosis. Cmaj, 2008, 178, 825-836.	2.0	196
64	Spectroscopy of human plasma for diagnosis of idiopathic Parkinson's disease. Biomarkers in Medicine, 2008, 2, 229-238.	1.4	24
65	NEUROLOGIC IMPAIRMENT DUE TO VITAMIN E AND COPPER DEFICIENCIES IN CELIAC DISEASE. Neurology, 2008, 71, 860-861.	1.1	39
66	Biomarker potential of heme oxygenase-1 in Alzheimer's disease and mild cognitive impairment. Biomarkers in Medicine, 2007, 1, 375-385.	1.4	23
67	MicroRNA Expression in Alzheimer Blood Mononuclear Cells. Gene Regulation and Systems Biology, 2007, 1, GRSB.S361.	2.3	166
68	Brain Erythropoietin Receptor Expression in Alzheimer Disease and Mild Cognitive Impairment. Journal of Neuropathology and Experimental Neurology, 2007, 66, 389-398.	1.7	76
69	Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiology of Aging, 2007, 28, 1795-1809.	3.1	168
70	The role of biologic markers in the diagnosis of Alzheimer's disease. , 2007, 3, 325-332.		18
71	Astroglia overexpressing heme oxygenase-1 predispose co-cultured PC12 cells to oxidative injury. Journal of Neuroscience Research, 2007, 85, 2186-2195.	2.9	54
72	Oxysterols, cholesterol homeostasis, and Alzheimer disease. Journal of Neurochemistry, 2007, 102, 1727-1737.	3.9	159

#	Article	IF	CITATIONS
73	Effects of heme oxygenase-1 expression on sterol homeostasis in rat astroglia. Free Radical Biology and Medicine, 2007, 42, 864-871.	2.9	52
74	Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiology of Aging, 2006, 27, 252-261.	3.1	181
75	Characterization of α1-antitrypsin as a heme oxygenase-1 suppressor in Alzheimer plasma. Neurobiology of Disease, 2006, 24, 89-100.	4.4	54
76	Over-expression of heme oxygenase-1 promotes oxidative mitochondrial damage in rat astroglia. Journal of Cellular Physiology, 2006, 206, 655-663.	4.1	103
77	Astroglial cytoprotection by erythropoietin pre-conditioning: implications for ischemic and degenerative CNS disorders. Journal of Neurochemistry, 2005, 93, 392-402.	3.9	47
78	Heme oxygenase expression in human central nervous system disorders. Free Radical Biology and Medicine, 2004, 37, 1995-2011.	2.9	226
79	Heme Oxygenaseâ€1: Transducer of Pathological Brain Iron Sequestration under Oxidative Stress. Annals of the New York Academy of Sciences, 2004, 1012, 84-93.	3.8	106
80	Redox Neurology: Visions of an Emerging Subspecialty. Annals of the New York Academy of Sciences, 2004, 1012, 342-355.	3.8	14
81	Evaluation of HFE (hemochromatosis) mutations as genetic modifiers in sporadic AD and MCI. Neurobiology of Aging, 2004, 25, 465-474.	3.1	57
82	Brain iron deposition and the free radical-mitochondrial theory of ageing. Ageing Research Reviews, 2004, 3, 265-301.	10.9	163
83	Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics, 2003, 3, 2240-2248.	2.2	106
84	Stress protein expression in the Alzheimer-diseased choroid plexus. Journal of Alzheimer's Disease, 2003, 5, 171-177.	2.6	48
85	Glial heme oxygenase-1 in CNSinjury and disease. Advances in Molecular and Cell Biology, 2003, 31, 869-882.	0.1	0
86	Heme Oxygenase-1 and Alzheimer Disease. , 2002, , 145-155.		4
87	Characterization of intracellular aggregates using fluorescently-tagged polyglutamine-expanded androgen receptor. Neurotoxicity Research, 2001, 3, 259-275.	2.7	10
88	Role of heme oxygenase-1 in the regulation of manganese superoxide dismutase gene expression in oxidatively-challenged astroglia. Journal of Cellular Physiology, 2000, 185, 80-86.	4.1	115
89	Characterization of cis-acting elements in the promoter of the mouse metallothionein-3 gene. FEBS Journal, 2000, 267, 1743-1753.	0.2	23
90	Increased T-type Ca2+ channel activity as a determinant of cellular toxicity in neuronal cell lines expressing polyglutamine-expanded human androgen receptors. Molecular and Cellular Biochemistry, 2000, 203, 23-31.	3.1	15

#	Article	IF	CITATIONS
91	Glial HO-1 expression, iron deposition and oxidative stress in neurodegenerative diseases. Neurotoxicity Research, 1999, 1, 57-70.	2.7	70
92	Cysteamine Pretreatment of the Astroglial Substratum (Mitochondrial Iron Sequestration) Enhances PC12 Cell Vulnerability to Oxidative Injury. Experimental Neurology, 1999, 160, 376-385.	4.1	34
93	Stress, Aging, and Neurodegenerative Disorders: Molecular Mechanismsa. Annals of the New York Academy of Sciences, 1998, 851, 429-443.	3.8	47
94	Aging glia may not protect neurons. Annals of Neurology, 1998, 44, 987-987.	5.3	3
95	Experimental induction of corpora amylacea in adult rat brain. , 1998, 43, 43-48.		20
96	Astrocyte Mitochondria: A Substrate for Iron Deposition in the Aging Rat Substantia Nigra. Experimental Neurology, 1998, 152, 188-196.	4.1	54
97	Spinobulbar muscular atrophy: polyglutamine-expanded androgen receptor is proteolytically resistant in vitro and processed abnormally in transfected cells. Human Molecular Genetics, 1998, 7, 379-384.	2.9	54
98	A Cellular Stress Model for the Differential Expression of Glial Lysosomal Cathepsins in the Aging Nervous System. Experimental Neurology, 1997, 147, 221-228.	4.1	24
99	Astrocytes, brain aging, and neurodegeneration. Neurobiology of Aging, 1996, 17, 467-480.	3.1	123
100	Headache and Scalp Edema in Sickle Cell Disease. Canadian Journal of Neurological Sciences, 1996, 23, 224-226.	0.5	3
101	Mapping of the basal forebrain cholinergic system of the dog: A choline acetyltransferase immunohistochemical study. Journal of Comparative Neurology, 1996, 366, 717-725.	1.6	27
102	Mitochondrial constituents of corpora amylacea and autofluorescent astrocytic inclusions in senescent human brain. Glia, 1995, 14, 55-64.	4.9	59
103	Iron-mediated bioactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in glial cultures. Glia, 1995, 15, 203-206.	4.9	44
104	Redox perturbations in cysteamine-stressed astroglia: Implications for inclusion formation and gliosis in the aging brain. Free Radical Biology and Medicine, 1995, 19, 823-835.	2.9	47
105	Differential effects of cysteamine on heat shock protein induction and cytoplasmic granulation in astrocytes and glioma cells. Molecular Brain Research, 1995, 31, 173-184.	2.3	37
106	A Cellular Stress Model for the Sequestration of Redoxâ€Active Glial Iron in the Aging and Degenerating Nervous System. Journal of Neurochemistry, 1995, 64, 1868-1877.	3.9	41
107	Composition of Gomori-positive inclusions in astrocytes of the hypothalamic arcuate nucleus. The Anatomical Record, 1994, 240, 407-415.	1.8	33
108	The 21-aminosteroid antioxidant, U74389F, prevents estradiol-induced depletion of hypothalamic β-endorphin in adult female rats. Brain Research, 1994, 652, 161-163.	2.2	11

#	Article	IF	CITATIONS
109	The origin and composition of peroxidase-positive granules in cysteamine-treated astrocytes in culture. Brain Research, 1994, 633, 9-20.	2.2	43
110	Role of the Cellular Stress Response in the Biogenesis of Cysteamine-Induced Astrocytic Inclusions in Primary Culture. Journal of Neurochemistry, 1993, 61, 1755-1765.	3.9	28
111	Pathologic Effect of Estradiol on the Hypothalamus. Biology of Reproduction, 1993, 49, 647-652.	2.7	67
112	Cysteamine Gliopathy in situ. Journal of Neuropathology and Experimental Neurology, 1993, 52, 399-410.	1.7	30
113	Comori-positive astrocytes: Biological properties and implications for neurologic and neuroendocrine disorders. Clia, 1991, 4, 365-377.	4.9	53
114	Statin immunolocalization in human brain tumors. Detection of noncycling cells using a novel marker of cell quiescence. Cancer, 1991, 68, 786-792.	4.1	25
115	Gomori-positive astrocytes in primary culture: effects of in vitro age and cysteamine exposure. Developmental Brain Research, 1990, 54, 71-79.	1.7	35